113 related articles for article (PubMed ID: 1326002)
1. Control of human B cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies.
Durandy A; Brousse N; Rozenberg F; De Saint Basile G; Fischer AM; Fischer A
J Clin Invest; 1992 Sep; 90(3):945-52. PubMed ID: 1326002
[TBL] [Abstract][Full Text] [Related]
2. Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice.
Durandy A; Emilie D; Peuchmaur M; Forveille M; Clement C; Wijdenes J; Fischer A
J Immunol; 1994 Jun; 152(11):5361-7. PubMed ID: 8189054
[TBL] [Abstract][Full Text] [Related]
3. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.
Fischer A; Blanche S; Le Bidois J; Bordigoni P; Garnier JL; Niaudet P; Morinet F; Le Deist F; Fischer AM; Griscelli C
N Engl J Med; 1991 May; 324(21):1451-6. PubMed ID: 2023604
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
5. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
6. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
7. CD21 is a ligand for CD23 and regulates IgE production.
Aubry JP; Pochon S; Graber P; Jansen KU; Bonnefoy JY
Nature; 1992 Aug; 358(6386):505-7. PubMed ID: 1386409
[TBL] [Abstract][Full Text] [Related]
8. CD23/CD21 interaction is required for presentation of soluble protein antigen by lymphoblastoid B cell lines to specific CD4+ T cell clones.
Grosjean I; Lachaux A; Bella C; Aubry JP; Bonnefoy JY; Kaiserlian D
Eur J Immunol; 1994 Dec; 24(12):2982-6. PubMed ID: 7805725
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to murine CD40 protect normal and malignant B cells from induced growth arrest.
Santos-Argumedo L; Gordon J; Heath AW; Howard M
Cell Immunol; 1994 Jul; 156(2):272-85. PubMed ID: 7517793
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
11. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
12. NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant.
Zhou W; Ohdan H; Tanaka Y; Hara H; Tokita D; Onoe T; Asahara T
Transpl Immunol; 2003; 12(1):9-18. PubMed ID: 14551028
[TBL] [Abstract][Full Text] [Related]
13. B-Cell suppression in adult mice injected with anti-delta followed by anti-mu mAb.
Chentoufi AA; Nizet Y; Havaux X; Nisol F; Bazin H; Latinne D
Cell Immunol; 2000 Oct; 205(1):40-51. PubMed ID: 11078606
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic prospects and lymphoproliferative syndromes related to EBV].
Durandy A
Ann Med Interne (Paris); 1997; 148(5):379-84. PubMed ID: 9538413
[TBL] [Abstract][Full Text] [Related]
15. EBV human B-cell lymphomas in Scid mice: description of the model and study of the role of anti-CD40 and anti-CD23 monoclonal antibodies in their development.
Garnier JL; Cannon MJ; Chargui J; Touraine JL; Cooper NR
Transplant Proc; 1993 Feb; 25(1 Pt 2):1387-8. PubMed ID: 7680156
[No Abstract] [Full Text] [Related]
16. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.
Yoshida M; Rybak RJ; Choi Y; Greenberg SJ; Barcos M; Kawata A; Matsuno F; Tsai H; Seon BK
Cancer Res; 1997 Feb; 57(4):678-85. PubMed ID: 9044845
[TBL] [Abstract][Full Text] [Related]
17. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
18. Cross-linking of CD23 antigen by its natural ligand (IgE) or by anti-CD23 antibody prevents B lymphocyte proliferation and differentiation.
Luo HY; Hofstetter H; Banchereau J; Delespesse G
J Immunol; 1991 Apr; 146(7):2122-9. PubMed ID: 1826018
[TBL] [Abstract][Full Text] [Related]
19. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
Nemerow GR; McNaughton ME; Cooper NR
J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
